

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1. (Original) A vaccine composition comprising an immunoadjuvant compound, wherein said immunoadjuvant compound consists of a Rho GTPase activator.
2. (Original) A vaccine composition according to claim 1 wherein said immunoadjuvant compound is selected from the group consisting of: a polypeptide comprising the amino acid sequence starting at the amino acid residue 720 and ending at the amino acid residue 1014 of sequence SEQID N°1, - a polypeptide comprising the amino acid sequence starting at the amino acid residue 720 and ending at the amino acid residue 1014 of sequence SEQ ID N°2, a polypeptide comprising the amino acid sequence starting at the amino acid residue 720 and ending at the amino acid residue 1014 of sequence SEQID N°3, a polypeptide comprising the amino acid sequence starting at the amino acid residue 1146 and ending at the amino acid residue 1451 of sequence SEQID N°4, a polypeptide comprising the amino acid sequence SEQID N°5, a polypeptide comprising the amino acid sequence SEQ ID N°6, a polypeptide comprising the amino acid sequence SEQ ID N°7, a polypeptide comprising the amino acid sequence SEQID N°8, and a polypeptide comprising the amino acid sequence SEQID N°9.
3. (Original) A vaccine composition according to claim 1 wherein said immunoadjuvant compound is selected from the group consisting of : a polypeptide comprising the amino acid sequence SEQ ID N°1, a polypeptide comprising the amino acid sequence SEQ ID N°2, a polypeptide comprising the amino acid sequence SEQID ID N°2, a polypeptide comprising the amino acid sequence SEQID

N°3, and a polypeptide comprising the amino acid sequence SEQID N°4.

4. (Original) A vaccine composition according to claim 1, wherein said immunoadjuvant compound is a protein comprising a polypeptide consisting of; from the N-terminal end to the C-terminal end, respectively : a) the injection domain of a Rho GTPase activator, and b) the catalytic domain of a Rho GTPase activator.

5. (Original) A vaccine composition according to claim 4, wherein said injection domain of a Rho GTPase activator is a polypeptide selected from the group consisting of: - a polypeptide comprising the amino acid sequence starting at the amino acid residue 1 and ending at the amino acid residue 719 of sequence SEQ ID N°1 ; - a polypeptide comprising the amino acid sequence starting at the amino acid residue 1 and ending at the amino acid residue 719 of sequence SEQ ID N°2 ; - a polypeptide comprising the amino acid sequence starting at the amino acid residue 1 and ending at the amino acid residue 719 of sequence SEQ ID N°3 ; and - a polypeptide comprising the amino acid sequence starting at the amino acid residue 1 and ending at the amino acid residue 1145 of sequence SEQ ID N°4.

6. (Currently Amended) A vaccine composition according to claim 4 ~~anyone of claims 4 and 5~~, wherein said catalytic domain of a Rho GTPase activator is a polypeptide selected from the group consisting of: - a polypeptide comprising the amino acid sequence starting at the amino acid residue 720 and ending at the amino acid residue 1014 of sequence SEQ ID N°1, a polypeptide comprising the amino acid sequence starting at the amino acid residue 720 and ending at the amino acid residue 1014 of sequence SEQ ID N°2, a polypeptide comprising the amino acid sequence starting at the amino acid residue 720 and ending at the amino acid residue 1014 of sequence SEQ ID N°3, - a polypeptide

comprising the amino acid sequence starting at the amino acid residue 1146 and ending at the amino acid residue 1451 of sequence SEQ ID N°4, - a polypeptide comprising the amino acid sequence SEQ ID N°5, - a polypeptide comprising the amino acid sequence SEQ ID N°6, - a polypeptide comprising the amino acid sequence SEQ ID N°7, - a polypeptide comprising the amino acid sequence SEQ ID N°8, and - a polypeptide comprising the amino acid sequence SEQ ID N°9.

7. (Currently Amended) A vaccine composition according to claim 1 ~~anyone of claim 1-6~~ comprising further an antigen.

8. (Original) A vaccine composition according to claim 7 wherein the antigen is selected from the group consisting of a hormone, a protein, a drug, an enzyme, a vaccine composition against bacterial, viral, fungal, prion, or parasitic infections, a component produced by microorganisms, inactivated bacterial toxins such as cholera toxin, ST and LT from Escherichia coli, tetanus toxin from Clostridium tetani, and proteins derived from HIV viruses.

9. (Currently Amended) A vaccine composition according to claim 1 ~~anyone of claims 1-8~~ for administration to a mucosal surface.

10. (Currently Amended) A vaccine composition according to claim 1 ~~anyone of claims 1-9~~, for an oral administration.

11. (Currently Amended) A protein comprising a polypeptide consisting of; from the N-terminal end to the C-terminal end, respectively: a) the injection domain of a Rho GTPase activator according to ~~anyone of claims 4 and 5~~, and b) the catalytic domain of a Rho GTPase activator according to claim 4. ~~anyone of claims 4 and 6~~.

12. (Cancelled)

13. (Cancelled)

14. (New) A vaccine composition according to claim 5, wherein said catalytic domain of a Rho GTPase activator is a polypeptide selected from the group consisting of: - a polypeptide comprising the amino acid sequence starting at the amino acid residue 720 and ending at the amino acid residue 1014 of sequence SEQ ID N°1, a polypeptide comprising the amino acid sequence starting at the amino acid residue 720 and ending at the amino acid residue 1014 of sequence SEQ ID N°2, a polypeptide comprising the amino acid sequence starting at the amino acid residue 720 and ending at the amino acid residue 1014 of sequence SEQ ID N°3, - a polypeptide comprising the amino acid sequence starting at the amino acid residue 1146 and ending at the amino acid residue 1451 of sequence SEQ ID N°4, - a polypeptide comprising the amino acid sequence SEQ ID N°5, - a polypeptide comprising the amino acid sequence SEQ ID N°6, - a polypeptide comprising the amino acid sequence SEQ ID N°7, - a polypeptide comprising the amino acid sequence SEQ ID N°8, and - a polypeptide comprising the amino acid sequence SEQ ID N°9.

15. (New) A method for preparing a comprising, adding the polypeptide according to claim 1 to an excipient.

16. (New) A method for preparing a comprising, adding the polypeptide according to claim 11 to an excipient.